Hepatic lipid quantity and quality in type 2 diabetes mellitus

Shimizu, Kahori; Shindou, Hideo; Tomita, Koji et al.

Frontiers in Pharmacology, 2026, 17, 1816958

Number of Access:412（2026-11-12 09:49 Counts）

Identifier to cite or link to this item: https://hdl.handle.net/11094/106054

Link to primary information 

File Format Terms of use Size Views Date.Available Description information
FrontPharmacol_17_1816958 pdf None 2.26 MB 44 2026.08.07  
Creative Commons : Attribution

Item Information

Output File Export EndNote Basic Export Mendeley

Title
Hepatic lipid quantity and quality in type 2 diabetes mellitus
Creator
NRID
1000050737749 1000050737749
ORCID
0000-0003-1574-5526 0000-0003-1574-5526
researchmap permalink
kahorishimizu kahorishimizu
CreatorName
Shimizu, Kahori
NRID
1000010401027 1000010401027
CreatorName
Shindou, Hideo
CreatorName
Tomita, Koji
NRID
1000050311387 1000050311387
ORCID
0000-0003-0594-8178 0000-0003-0594-8178
researchmap permalink
read0165079 read0165079
Scopus Author ID
57195381326 57195381326
CreatorName
Mizuguchi, Hiroyuki
Subject
lipid intermediate
lipid quality
lipid quantity
phospholipid diversity
type 2 diabetes mellitus
Description
Shimizu K., Shindou H., Tomita K., et al. Hepatic lipid quantity and quality in type 2 diabetes mellitus. Frontiers in Pharmacology 17, 1816958 (2026); https://doi.org/ 10.3389/fphar.2026.1816958.
Abstract
The incidence of type 2 diabetes mellitus (T2DM) has been increasing worldwide. In the pathophysiology of metabolic diseases, including T2DM, both the quantity and quality of lipids that accumulate in the body have attracted significant research attention. Excess lipids accumulate in non-adipose tissues, such as the liver and skeletal muscles, leading to insulin resistance and an increased risk of developing T2DM. The liver is the central organ for glucose and lipid metabolism, and impaired hepatic regulatory mechanisms lead to hyperglycemia, insulin resistance, and hepatic lipid accumulation. Hepatic triglyceride (TG) accumulation contributes to the development of hepatic insulin resistance; however, the quantity of TGs alone is insufficient to explain the development of glucose and lipid metabolic dysfunctions. Thus, we focus on lipid quality, particularly fatty acids. In addition to TGs, phospholipids store fatty acids, which vary in carbon chain length, number of double bonds, and position of double bonds (such as ω3 and ω6), resulting in lipid diversity. Changes in the fatty acid chains of phospholipids are also strongly associated with glucose and lipid metabolism. In this mini review, we discuss the involvement of hepatic lipid quantity and quality in T2DM, with the aim of contributing to the development of novel T2DM therapies.
Publisher
Frontiers Media SA
Source Title
Frontiers in Pharmacology
Volume (Issue)
17
Page
1816958
Date of Issued
2026-05-29
Language
English
Handle URL
https://hdl.handle.net/11094/106054
eISSN
16639812
Relation.isIdenticalTo
DOI (Publisher Version)
https://doi.org/10.3389/fphar.2026.1816958
Access Rights
open access
CopyRight
This article is licensed under a Creative Commons Attribution 4.0 International License.
oaire:version
Version of Record
Category
学術雑誌論文 Journal Article